Equities

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)29.98
  • Today's Change1.24 / 4.31%
  • Shares traded4.76m
  • 1 Year change-36.20%
  • Beta0.8939
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, cash reserves at Apellis Pharmaceuticals Inc fell by 200.78m. Cash Flow from Financing totalled 394.50m or 99.47% of revenues. In addition the company used 594.74m for operations while cash used for investing totalled 674.00k.
Cash flow per share-2.02
Price/Cash flow per share--
Book value per share1.94
Tangible book value per share1.94
More ▼

Balance sheet in USDView more

Apellis Pharmaceuticals Inc has a Debt to Total Capital ratio of 65.60%, a lower figure than the previous year's 167.26%.
Current ratio4.36
Quick ratio3.73
Total debt/total equity1.91
Total debt/total capital0.656
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.